A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Part of paid clinical trials in Chula Vista, California.

Sponsor
Alnylam Pharmaceuticals
Study ID
NCT07465224
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ALN-4324 — DRUG
    ALN-4324 will be administered subcutaneously (SC).
  • Placebo — DRUG
    Placebo will be administered SC.

Study Details

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Key Dates

Start date
Jan 15, 2026
Status verified
May 2026
Primary completion
May 28, 2027
Completion
May 28, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ALN-4324
    Participants will be administered a single dose of ALN-4324.
  • Placebo Comparator: Placebo
    Participants will be administered a single dose of placebo.

Primary Outcome Measure

Change from Baseline in M-value [ Time Frame: Baseline up to Month 3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Clinical Trial SiteChula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By research site
Clinical Trial Site· Chula Vista, CA

Related Studies